AEMD Overview

American Eagle Outfitters Performance: American Eagle Outfitters Inc. reported third-quarter revenue of $1.36 billion and adjusted earnings of 53 cents per share, both exceeding analyst expectations, leading to a 14.8% increase in share price during pre-market trading.

Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Powell Max Ltd (up 70%), Creative Media & Community Trust Corp (up 53.3%), and SMX (up 27.3%).

Significant Losers: Lulu’s Fashion Lounge Holdings Inc. experienced a dramatic drop of 58.3%, while ScanTech AI Systems Inc. fell 35.8% after receiving a delisting determination from Nasdaq.

Market Reactions: The overall market showed mixed reactions with various companies reporting earnings and guidance updates, impacting their stock prices significantly in pre-market trading.

Financial Performance: Aethlon Medical reported a 48% reduction in operating expenses for the fiscal second quarter ended September 30, 2025, resulting in an operating loss of $1.5 million, down from $2.8 million in the previous year.

Clinical Progress: Recruitment for the second cohort of the Australian oncology trial using the Hemopurifier has begun, focusing on patients with solid tumors who have not responded to PD-1 therapy, with initial results showing potential decreases in extracellular vesicle concentrations.

Scientific Collaboration: The company is collaborating with UCSF on Long COVID research, analyzing extracellular vesicle cargo from patient samples, and preparing a manuscript for peer review.

Operational Updates: Aethlon has resolved compliance issues with Nasdaq, maintaining its listing, and is exploring the compatibility of the Hemopurifier with a simplified blood treatment system for future oncology applications.

Financial Results Announcement: Aethlon Medical, Inc. will release its fiscal second quarter financial results on November 12, 2025, followed by a conference call to discuss the results and corporate developments.

Hemopurifier Overview: The Aethlon Hemopurifier is an investigational device designed to remove enveloped viruses and tumor-derived extracellular vesicles from the bloodstream, holding a Breakthrough Device Designation for treating advanced cancer and life-threatening viruses.

Conference Call Registration: Interested participants can register for the conference call online or by phone, with a replay available for a month after the call.

Company Background: Aethlon Medical, based in San Diego, focuses on developing medical devices to address unmet needs in oncology and infectious diseases through innovative technology.